Loading clinical trials...

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

NCT03104621•Gangnam Severance Hospital

View on ClinicalTrials.gov

Summary

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and preservative-free 0.0015% tafluprost will reduce intraocular pressure significantly. In addition, preservative-free 0.0015% tafluprost might improve tolerability of glaucoma patients.

Eligibility

Age

20 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1\. Primary open angle glaucoma and normotensive glaucoma patients who came to the outpatient clinic for regular glaucoma check-ups were enrolled.
•2\. Glaucoma was defined as the patients who had open angle confirmed by gonioscopy, optic nerve cupping (a vertical cup-disc ratio of \>0.6) and or notching of the neuroretinal rim and or retinal nerve fiber defects characteristics of glaucoma, and visual field defect(i.e., a glaucoma hemi-filed test result outside normal limits, a pattern standard deviation probability of \<5%, or a cluster of three or more non-edge points in location typical of glaucoma, all of which were depressed on a pattern deviation plot at a P level of \<5%, and at least one of which was depressed at a P level of \<1% on two consecutive visual field tests).
•3\. Normal tension glaucoma included criteria: repeated measurements of untreated IOP values of \< 21mmHg. Primary open angle glaucoma included criteria: repeated measurements of untreated IOP values of ≥ 22mmHg.

Exclusion Criteria

•1\. Phakic and pseudophakic eyes.
•2\. eyes that had been taken vitrectomy, trabeculectomy, or surgery influenced IOP

Key Dates

Start Date

March 1, 2013

Primary Completion Date

September 1, 2014

Completion Date

September 1, 2015

Last Updated

April 7, 2017

Enrollment

ACTUAL participants

Conditions

Primary Open-angle Glaucoma

Interventions

Benzalkonium chloride (BAK)

DRUG

0.0015% tafluprost

DRUG

PRESERFLO® MicroShunt Extension Study

NCT04333433

Primary Open-angle Glaucoma

View study

UNKNOWN

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

NCT04036214

Primary Open-Angle Glaucoma, Unspecified EyeOcular Hypertension

View study

COMPLETEDNA

Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 7, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

Inclusion Criteria

Exclusion Criteria

PRESERFLO® MicroShunt Extension Study

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6